← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 2000First marketed drug
Dec 21, 2012First NDA
Dec 21, 2012Last known activity
Nov 14, 2018
Acquired by Amryt Research Limited → Chiesi on May 21, 2019
Timeline
1980s
- Jul 1, 1981
Novelion Therapeutics— Founded
2010s
- Dec 21, 2012
lomitapide— NDA Organization
- Dec 21, 2012
lomitapide— NDA Secondary Org
- Feb 24, 2014
metreleptin— Marketing Organization
- May 21, 2019
Amryt Research Limited— Acquired By
2020s
- Jan 9, 2023
Chiesi— Now
Drugs by trial phase (33 distinct, 52 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (19 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acne Vulgaris
- Basal Cell Carcinoma
- Basal Cell Nevus Syndrome
- Blindness
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Choroidal Neovascularization
- Conjunctivitis
- Conjunctivitis, Allergic
- Glaucoma
- Glaucoma, Open-Angle
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemia Type II
- Hyperplasia
- Hypertension
- Kidney Diseases
- Kidney Failure, Chronic
- Leber Congenital Amaurosis
- Lipodystrophy
- Lipodystrophy, Congenital Generalized
- Lower Urinary Tract Symptoms
- Lung Neoplasms
- Macular Degeneration
- Melanoma
- Neovascularization, Pathologic
- Ocular Hypertension
- Prostatic Hyperplasia
- Retinitis
- Retinitis Pigmentosa
- Rosacea
- Syndrome
Marketed drugs (2)
Recent trials (50)
- NCT04026178Lead sponsorPhase 4Nov 14, 2018
- NCT04026178Study chairPhase 4Nov 14, 2018
- NCT02765841Lead sponsorPhase 3May 1, 2016
- NCT02173158Lead sponsorPhase 3Apr 1, 2014
- NCT02080468Lead sponsorPhase 1Feb 1, 2014
- NCT02080455Lead sponsorPhase 1Feb 1, 2014
- NCT01999764Lead sponsorPhase 2Nov 1, 2013
- NCT01999764Study directorPhase 2Nov 1, 2013
- NCT02044419Lead sponsorPhase 1Oct 1, 2013
- NCT02044419Study chairPhase 1Oct 1, 2013
- NCT01915771Lead sponsorPhase 1Aug 1, 2013
- NCT01760187Lead sponsorPhase 1Nov 1, 2012
- NCT01543906Study directorPhase 1Feb 1, 2012
- NCT01543906Lead sponsorPhase 1Feb 1, 2012
- NCT01521793Lead sponsorPhase 1Jan 1, 2012
Details
- Founded
- Vancouver, British Columbia, CA Jul 1, 1981
- First NDA
- Dec 21, 2012
- Last known activity
- Nov 14, 2018
Designations held
- Orphan drug
Notes
--- Notes from Aegerion: Acquired by Novelion 15 Jun 2016 --- --- Notes from QLT: Acquires Aegerion ---